Incyte and Secant Announce Partnership to Market and Further Develop the Genomics Knowledge Platform Palo Alto, CA and Cleveland, OH -- July 9, 2001 - Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomic information company, and Secant Technologies, a leading infrastructure software company, today announced a strategic partnership to market and further develop Incyte's Genomics Knowledge Platform (GKP), a software environment that represents a major breakthrough for life science researchers. Incyte will continue to market the Genomics Knowledge Platform to the life science community and support its existing customer base. In addition, the partnership provides Secant with an exclusive license to assume further development and marketing of the GKP and for Incyte to make an equity investment in Secant. The companies will also collaborate on professional services and support offerings for GKP customers. Financial terms were not disclosed. Development of Incyte's Genomics Knowledge Platform to date, has been the result of a significant collaboration with Secant Technologies over the past twenty months. Incyte and Secant have combined advances in both scientific research and high-performance enterprise computing. The Genomics Knowledge Platform allows life sciences researchers to integrate and analyze a variety of data types, including gene sequence, expression, polymorphism, and proteomic data, as well as functional data. "We constructed the Genomics Knowledge Platform to extend data integration beyond genomics to all science-based information types, including chemical and clinical. It's only natural, therefore, that the universal open architecture which allows for collaboration with other information providers and software creators can be better served by a company like Secant whose focus is software and data integration," said Roy A. Whitfield, Chief Executive Officer of Incyte. "Under the licensing agreement, Incyte will continue to market this e-research platform with our content to the life sciences community and our existing customer base." "We are excited about the market opportunity that lies ahead as a result of exclusively licensing the Genomics Knowledge Platform (GKP) from Incyte. This allows us to further develop the platform with our Model-Driven Infrastructure™ and SmartFarm™ parallel processing technologies, position the platform as an industry standard, and provide vertical solutions to additional markets that are not currently served by Incyte," said Jim Holt, President of Secant Technologies. The Genomics Knowledge Platform will continue to provide Incyte with the framework for its next generation of information products. About Incyte Genomics Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's website at www.incyte.com. About Secant Technologies Secant Technologies, Inc. provides model-driven infrastructure software that ensures the performance and scalability of the most complex and demanding applications. Software platforms powered by Secant have achieved high rate of success for companies like i2 Technologies and Open Telecommunications and will help to guarantee the success of the Genomics Knowledge Platform. Secant provides the power to perform. Secant has won awards from Network Computing and Java Developer's Journal, a Crossroads 2001 A-List Award and more. For more information, visit Secant's Web site at www.secant.com or call 1-888-473-2268. Except for the historical information contained herein, the matters set forth in this press release, including statements as to the expected impact that the release of the Genomics Knowledge Platform will have on the life sciences community and its utility to life sciences researchers, the ability of the partnership to establish the product as the standard in the biotechnology industry, the timing of the introduction and development of new products relating to the Genomics Knowledge Platform and future development and introduction of the Genomics Knowledge Platform into other non-biotechnology markets, and Incyte's ability to contribute to the understanding of disease and possible cures, to integrate a variety of data types, and to assist researchers in their drug discovery and development efforts, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, the extent of utilization of genomic information by researchers; risks relating to the development of new products and their use by third parties; the ability of the parties to implement technological advances and to effectively compete in a timely manner; the effects of competition and the introduction of competing products in the marketplace; the ability of the parties to develop new products based on the Genomics Knowledge Platform; the ability of Incyte and Secant to obtain and retain customers; and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2001. Incyte disclaims any intent or obligation to update these forward-looking statements.